Effects of Sympathicomimetic Agonists on the Disease Course and Mutant Allele Burden in Patients With JAK2-mutated Myeloproliferative Neoplasms. A Multicenter Phase II Trial.

Trial Profile

Effects of Sympathicomimetic Agonists on the Disease Course and Mutant Allele Burden in Patients With JAK2-mutated Myeloproliferative Neoplasms. A Multicenter Phase II Trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jan 2017

At a glance

  • Drugs Mirabegron (Primary)
  • Indications Myelofibrosis; Myeloproliferative disorders; Polycythaemia vera; Thrombocytopenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 06 Dec 2016 Primary endpoint (Reduction in the burden of mutated alleles of 50% at 24 weeks) has not been met, according to results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top